- Home
- SNN
SNN
Smith & Nephew SNATS Inc.
as 07-26-2024 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as Smith & Nephew SNATS Inc. SNN prepares to release earnings report on 01 Aug 2024.
| Founded: | 1856 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 1999 |
| Target Price: | $33.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 0.60 | EPS Growth: | 18.04 |
| 52 Week Low/High: | $21.53 - $30.73 | Next Earning Date: | 08-01-2024 |
| Revenue: | $5,549,000,000 | Revenue Growth: | 6.40% |
| Revenue Growth (this year): | 6.87% | Revenue Growth (next year): | 5.58% |
Latest Smith & Nephew SNATS Inc. News
SNN Breaking Stock News: Dive into SNN Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
Simply Wall St.
3 days ago
Admiral Group And 2 More UK Exchange Stocks Estimated As Below Intrinsic Value
Zacks
9 days ago
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
MT Newswires
10 days ago
Smith & Nephew Says Catalystem Primary Hip System Got FDA's Premarket Clearance
GlobeNewswire
10 days ago
Best-in-class just got better; Smith+Nephew announces 510(k) clearance of new CATALYSTEM™ Primary Hip System
Medical Device Network
14 days ago
Smith & Nephew sponsored player Jasmine Paolini reaches Wimbledon final
Morningstar Research
16 days ago
Analyst Report: Smith & Nephew plc
GlobeNewswire
17 days ago
Smith+Nephew is trailblazing a new path for female surgeons with its Orthopaedics for All initiative; a first-of-its-kind global advisory board
Compare SNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNN Smith & Nephew SNATS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.